Allegheny Health Network
Find a
Request An Appointment Login to
News Classes &
Call 412.Doctors

Active Clinical Trials

Improving Dulera Adherene

Active NCT:
Allegheny General Hospital
Allegheny General Hospital

Asthma Management Systems

For more information, please contact Allison Kong at 412-359-3328 or

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence


40 subjects with moderate-to-severe asthma will be randomly selected for study in which 20, will be monitored for medication use (Dulera 100/5, Dulera 200/5 and Proventil HFA) over 3 months. These intervention subjects will receive medication use feedback at each visit, while the control group will receive the standard of asthma care. Those interventional subjects with Dulera adherence<60% will receive feedback based on an asthma adherence disease management model protocol, Asthma Adherence Pathway. Intervention clinicians will been trained in Motivational Interviewing to reduce subject ambivalence about medication use. The primary hypothesis is that subjects who receive medication monitoring and Motivational Interviewing adherence strategies will have better asthma control, as measured by the Asthma Control Questionnaire, than the control group.

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Inclusion Criteria:

  • Physician diagnosis of asthma of moderate severity
  • Subjects ≥ 18 years of age
  • Currently receiving an inhaled corticosteroid medication and being prescribed Dulera 100/5 as part of standard of care based upon asthma severity and dosing guidelines
  • Asthma Control Questionnaire (ACQ) result > 1.0 at entry
  • Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)
  • History of reversible airway obstruction documented by treating physician Exclusion Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease; chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with Dulera

Exclusion Criteria:

  • Intermittent asthma (asthma exacerbations or symptoms < 3 days/week)
  • Diagnosis of emphysema in prior year
  • Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis, pulmonary hypertension or lung cancer
  • On any medication documented to have a drug interaction with Dulera